TY - JOUR T1 - Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation JF - medRxiv DO - 10.1101/2020.03.29.20041962 SP - 2020.03.29.20041962 AU - Ting Gao AU - Mingdong Hu AU - Xiaopeng Zhang AU - Hongzhen Li AU - Lin Zhu AU - Hainan Liu AU - Qincai Dong AU - Zhang Zhang AU - Zhongyi Wang AU - Yong Hu AU - Yangbo Fu AU - Yanwen Jin AU - Kaitong Li AU - Songtao Zhao AU - Yongjiu Xiao AU - Shuping Luo AU - Lufeng Li AU - Lingfang Zhao AU - Junli Liu AU - Huailong Zhao AU - Yue Liu AU - Weihong Yang AU - Jing Peng AU - Xiaoyu Chen AU - Ping Li AU - Yaoning Liu AU - Yonghong Xie AU - Jibo Song AU - Lu Zhang AU - Qingjun Ma AU - Xiuwu Bian AU - Wei Chen AU - Xuan Liu AU - Qing Mao AU - Cheng Cao Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/07/2020.03.29.20041962.abstract N2 - An excessive immune response contributes to SARS-CoV, MERS-CoV and SARS-CoV-2 pathogenesis and lethality, but the mechanism remains unclear. In this study, the N proteins of SARS-CoV, MERS-CoV and SARS-CoV-2 were found to bind to MASP-2, the key serine protease in the lectin pathway of complement activation, resulting in aberrant complement activation and aggravated inflammatory lung injury. Either blocking the N protein:MASP-2 interaction or suppressing complement activation can significantly alleviate N protein-induced complement hyper-activation and lung injury in vitro and in vivo. Complement hyper-activation was also observed in COVID-19 patients, and a promising suppressive effect was observed when the deteriorating patients were treated with anti-C5a monoclonal antibody. Complement suppression may represent a common therapeutic approach for pneumonia induced by these highly pathogenic coronaviruses.One Sentence Summary The lectin pathway of complement activation is a promising target for the treatment of highly pathogenic coronavirus induced pneumonia.Competing Interest StatementThe authors have declared no competing interest.Clinical Trial2020L00003Funding StatementNational Science and Technology Major Projects (2018ZX09711003-005-005 and 2018ZX09201017-007), National Basic Research Program of China (2012CB518902)Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is always available for researches interested in this study. ER -